Welcome to our dedicated page for Relmada Therapeutics SEC filings (Ticker: RLMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Relmada Therapeutics, Inc. (RLMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Relmada identifies itself in these documents as a Nevada corporation with common stock listed on the Nasdaq Capital Market under the symbol RLMD and principal offices in Coral Gables, Florida.
Through forms such as Form 8‑K, Relmada reports material events related to its business. Recent 8‑K filings describe topics including: written FDA feedback on planned Phase 3 registrational trials for NDV-01 in non-muscle invasive bladder cancer; preliminary nine‑month safety and efficacy data from the NDV-01 Phase 2 study; quarterly financial updates; an underwritten offering of common stock and pre-funded warrants; Nasdaq minimum bid price compliance matters; and amendments to executive employment agreements. These filings often incorporate press releases as exhibits and summarize key financial or clinical information referenced in company news.
Investors interested in capital structure and financing can review 8‑K disclosures regarding the terms of underwritten offerings, pre-funded warrants, and related legal opinions. Those focused on governance and compensation can examine filings detailing amended and restated employment agreements for executive officers, including changes to salary and severance provisions.
While this page emphasizes current and historical 8‑K reports, Relmada also files other periodic and registration statements, such as Forms 10‑Q, 10‑K, and S‑3, that contain more extensive financial statements, risk factor discussions, and descriptions of its NDV-01 and sepranolone development programs. Stock Titan enhances access to these documents by pairing them with AI-powered tools that help explain filing contents, highlight key sections, and make it easier to locate information on topics such as clinical trial plans, cash resources, listing status, and executive arrangements.
Relmada Therapeutics, Inc. (RLMD) – Form 4 insider filing: The company’s Chief Financial Officer, Maged Shenouda, was granted stock options for 600,000 common shares on 06/26/2025. The options carry an exercise price of $0.67 per share and will vest in 16 equal quarterly installments beginning 09/26/2025, fully vesting by 06/26/2035. Following the grant, Shenouda beneficially owns 600,000 derivative securities, reported as direct ownership. No shares were purchased or sold in the open market; this filing records an equity incentive award, aligning executive compensation with future shareholder value.
Relmada Therapeutics, Inc. (RLMD) filed a Form 4 disclosing a new equity award to director John Glasspool. On 06/26/2025, Glasspool received 100,000 non-qualified stock options with an exercise price of $0.67 per share. The options vest in 16 equal quarterly installments starting 09/26/2025 and expire on 06/26/2035. No common shares were bought or sold; the only reported transaction is the option grant, leaving Glasspool with 100,000 derivative securities held directly. The filing indicates normal onboarding compensation and modest potential dilution relative to RLMD’s outstanding share count (not provided in the document). Investors should view the grant as routine governance practice that aligns the new director’s incentives with long-term shareholder value without any immediate cash outlay or ownership change.